Dapsone is an anticatalysis for Alzheimer's disease exacerbation.
Level 3 - non-randomized controlled study
Non-randomized observational comparative study of patients categorized by dapsone exposure and Alzheimer's disease diagnosis.
PubMed 35542045 · doi:10.1016/j.isci.2022.104274
What was done
The authors evaluated patients with leprosy and Alzheimer's disease (AD) to investigate whether dapsone (4,4'-diaminodiphenyl sulfone), hypothesized to act as a cGAS/STING pathway inhibitor, affects AD risk. Participants were categorized into four comparison groups based on dapsone prescription (prescribed vs. unprescribed) and AD diagnosis status (diagnosed vs. undiagnosed).
What was found
The abstract reports no exact numerical data, sample sizes, effect sizes, confidence intervals, or p-values. It qualitatively states that comparing dapsone-prescribed to unprescribed groups showed a significantly reduced incidence and prevalence of AD in patients taking dapsone.
Why it matters
If validated, repurposing dapsone as an anti-inflammatory modulator of the cGAS/STING pathway could offer a low-cost preventive strategy for Alzheimer's disease neurodegeneration.
Limits
The abstract provides zero quantitative metrics, group counts, or statistical values. As an observational study in a specialized leprosy cohort, findings are vulnerable to residual confounding, selection bias, and lack of generalizability to broader populations with AD.
Cited by
- context A study by Lee et al. found that people not taking dapsone had a rate of Alzheimer's disease six times higher than those taking 100 mg of dapsone.